Early Statins Tied to 15% Lower Dementia Risk in Study

A 15-year Danish study links starting statins soon after a type 2 diabetes diagnosis with a 15% lower dementia risk, strengthening the heart-brain connection.

Researchers tracked 132,585 statin-naïve people in Denmark who developed type 2 diabetes between 2006 and 2019, with follow-up through 2021. Dr Tummas Ternhamar of Copenhagen University Hospital, who presented the findings at the European Society of Cardiology congress and in *The Lancet Regional Health – Europe*, reported that starting statins within one year of diagnosis was associated with a 15% lower relative risk of dementia over 10 years, compared with a 10% reduction for those starting between one and five years after diagnosis. During a median follow-up of 7.1 years, 2.7% of participants developed dementia, and results were similar in women and men.

The striking element is that the benefit appears to depend on when treatment begins: acting early after diagnosis looked better than acting late, a nuance the Copenhagen team says previous pooled analyses could not capture. The Guardian reports that the researchers said their findings 'add that timing matters within that – acting early looks better than acting late.' Prof Isabel Goncalves of the ESC communication committee, who was not involved in the research, hailed the findings, noting that because statins are widely available and inexpensive, the results are potentially important. The study also hints statins could one day sit alongside diet and exercise in dementia-prevention packages.

The study used a clone-censor-weight design to emulate a randomised trial and reduce observational bias, according to The Carer, which notes Dr Ternhamar's conclusion that statins 'seem to be underused' in people with type 2 diabetes. Gilmore Health News adds important caveats: the absolute risk differences were modest — estimated 10-year dementia risk was 3.9% without statins, 3.3% with early initiation, and 3.5% with later initiation — and prior evidence is mixed. According to Gilmore Health, a 2025 meta-analysis of over seven million people found a 14% lower dementia risk with statin use, while a 2021 analysis of older adults found no association. The British Heart Foundation's Prof Bryan Williams stressed the study shows association, not causation, though trial evidence makes the findings 'certainly plausible.'

The proposed mechanism runs through the blood vessels: statins lower LDL cholesterol, which drives plaque formation and can harden or narrow the vessels supplying the brain, disrupting blood flow and raising dementia risk. The Lancet dementia commission has identified high LDL-C from midlife as one of 14 modifiable risk factors that, if addressed, could prevent or delay 45% of dementia cases. Dr Honorine Lebraud of Alzheimer's Research UK said the study reinforces 'what is good for the heart is good for the brain,' while noting that more work is needed to show a direct link between statins and reduced dementia risk.

The stakes are large: the number of people living with dementia globally is forecast to nearly triple to 153 million by 2050, yet experts believe almost half of cases could be prevented or delayed. Statins are already among the most commonly used drugs worldwide, so any added brain-health benefit would be cheap and widely accessible, as Goncalves pointed out. Separately, RACGP's newsGP reports that Australia's STAREE trial — the first randomised controlled trial of statins in healthy people over 70, involving nearly 10,000 participants — found a daily 40 mg atorvastatin dose was associated with a 30% lower risk of heart attack and stroke, underlining the drugs' expanding preventive profile in ageing populations.

Researchers are still investigating exactly why statins might lower dementia risk, with Dr Ternhamar suggesting protection against cerebrovascular atherosclerosis, ischemic stroke and reduced blood flow offers a plausible explanation. According to The Guardian, he said the findings strengthen the idea that one day everyone might be offered statins as part of a package of measures — such as staying physically active and eating well — to reduce dementia risk. Gilmore Health notes the Danish researchers themselves concluded that randomised trial evidence is still needed, and that no one should start or stop statins for dementia reasons without consulting a clinician. For now, the study sharpens the case for detecting and treating high LDL-C from midlife.